|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Pediatric Neuro-Oncology |
Department of Pediatric Oncology, Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX 77030 (Z.E.D., D.H.M.); Department of Hematology/Oncology, Children's Hospital San Diego, San Diego, CA 92123 (R.P.K.); Departments of Pharmaceutical Sciences (C.F.S.) and Radiation Oncology (L.E.K.), St. Jude Children's Research Hospital, Memphis, TN 38105; Department of Surgery, Duke University Medical Center, Durham, NC 27710 (H.S.F.); St. Luke's Episcopal Hospital, Houston, TX 77030 (C.W.M.); Department of Pathology, Johns Hopkins Hospital, Baltimore, MD 21287 (P.C.B.); Department of Clinical Biostatistics, Roswell Park Cancer Institute, Buffalo, NY 14263 (J.K.); Division of Pediatric Hematology/Oncology, University of New Mexico School of Medicine, Albuquerque, NM 87131 (R.L.H.); USA
1 Address correspondence to ZoAnn E. Dreyer, Texas Children's Cancer Center at Baylor College of Medicine, Pediatric Oncology, 6621 Fannin Street CC1510, Houston, TX 77030-2399, USA (zdreyer{at}bcm.tmc.edu).
Abstract
Idarubicin (IDA), the 4-demethoxy analog of daunomycin, has had significant cytotoxicity in many malignancies. In previous reports, the alcohol metabolite of IDA, 4-demethoxydaunorubicinol (idarubicinol, or IDOL), had cytotoxic activity and the ability to penetrate the blood-brain barrier. For this reason, the Pediatric Oncology Group conducted a Phase 2 trial of IDA for children with recurrent or progressive brain tumors. Ninety-one eligible children were entered on this study, with ages ranging from 3 months to 19 years. Patients were stratified by tumor types into 6 categories: stratum 1, low-grade astrocytoma; stratum 2, malignant glioma (glioblastoma multiforme and anaplastic astrocytoma); stratum 3, medulloblastoma; stratum 4, brainstem glioma; stratum 5, ependymoma; and stratum 6, miscellaneous malignant tumors not included in the previous diagnoses. IDA (18 mg/m2) was infused over 4 h and followed by granulocyte colony-stimulating factor (G-CSF) beginning day 5 after infusion of IDA. G-CSF was continued until blood cell count recovery. Cycles were repeated at approximately 21-day intervals until patients developed progressive disease or had completed 6 cycles with stable or improved disease. Pharmacokinetic plasma and cerebrospinal fluid (CSF) samples were collected from a subset of these patients. Response was poor in all strata. Most patients developed progressive disease; however, in 21 patients with medulloblastoma there was 1 partial response, and 6 patients had stable disease (SD) that in 4 patients lasted more than 20 weeks. Grades 3/4 hematopoietic toxicities were the most common toxic events, and 14 infection-related events resulted in hospitalization of patients. Only 1 patient developed reduced cardiac function. The systemic clearance data for IDA and IDOL were nearly identical to those published on patients with leukemia, and the plasma elimination of the IDOL metabolite was substantially longer than that of the parent drug IDA. The peak CSF:plasma ratios of IDA and IDOL were very low. The overall response rates to IDA were disappointing despite periods of prolonged SD in nearly a fourth of the patients. We conclude from this data and from that in nonhuman primates that it is unlikely that IDA, daunomycin, or other related anthracyclines will be useful for treating primary CNS tumors.
References
Arndt, C.A., Krailo, M.D., Steinherz, L., Scheithauer, B., Liu-Mares, W., and Reaman, G.H. (1998) A phase II clinical trial of idarubicin administered to children with relapsed brain tumors. Cancer 83,813 -816.[Medline]
Berg, S.L., Reid, J., Godwin, K., Murry, D.J., Poplack, D.G., Balis, F.M., and Ames, M.M. (1999) Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. J. Pediatr. Hematol. Oncol. 21,26 -30.[Medline]
Bushunow, P., Mechtler, L., Mogensen, K., Winfield, J., Lemke, S., and Coyle, T. (1998) Idarubicin for treatment of recurrent malignant glial tumors: A Buffalo-Rochester-Syracuse Neuro-oncology Study Group trial. Proc. Am. Soc. Clin. Oncol. 17, 386a (abstract).
Daghestani, A., Arlin, Z.A., Leyland-Jones, B., Gee, T.S., Kempin,
S.J., Mertelsmann, R., Budman, D., Schulman, P., Baratz, R., Williams, L.,
Clarkson, B., and Young, C. (1985) Phase I and II clinical and
pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult
patients with acute leukemia. Cancer Res.
45,1408
-1412.
de Graff, S.S., Riley-Stewart, C.A., and Evans, W.E. (1989) Improved high-performance liquid chromatographic method using loop-column extraction for analysis of idarubicin and idarubicinol in plasma. J. Chromatogr. A 491,501 -506.[CrossRef]
Gehan, E.A. (1961) The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J. Chronic Dis. 13,346 -353.[CrossRef][ISI][Medline]
Izumoto, S., Arita, N., Hayakawa, T., Ohnishi, T., Taki, T., Yamamoto, H., and Ushio, Y. (1990) Effect of MX2, a new morpholino anthracycline, against experimental brain tumors. Anticancer Res. 10,735 -739.[Medline]
Kuffel, M.J., Reid, J.M., and Ames, M.M. (1992) Anthracyclines and their C-13 alcohol metabolites: Growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother. Pharmacol. 30, 51-57.[CrossRef][ISI][Medline]
NCI, National Cancer Institute. (1993) Investigators Handbook. A Manual for Participants in Clinical Trials of Investigational Agents Sponsored by the Division of Cancer Treatment, National Cancer Institute. Washington, D.C.: Department of Health and Human Services,153 -157.
Reid, J.M., Pendergrass, T.W., Krailo, M.D., Hammond, G.D., and
Ames, M.M. (1990) Plasma pharmacokinetics and cerebrospinal fluid
concentrations of idarubicin and idarubicinol in pediatric leukemia patients:
A Children's Cancer Study Group report. Cancer Res.
50,6525
-6528.
Schott, B., and Robert, J. (1989) Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells. Biochem. Pharmacol. 38,169 -172.
Speth, P.A., Minderman, H., and Haanen, C. (1989) Idarubicin v daunorubicin: Preclinical and clinical pharmacokinetic studies. Semin. Oncol. 16,2 -9.
Tan, C.T., Hancock, C., Steinherz, P., Bacha, D.M., Steinherz, L.,
Luks, E., Winick, N., Meyers, P., Mondora, A., Dantis, E., Niedzwiecki, D.,
and Stevens, Y. (1987) Phase I and clinical pharmacological study
of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
Cancer Res. 47,2990
-2995.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
